Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-expressing Advanced Solid Tumors”

46 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 46 results

Testing effectiveness (Phase 2)Looking for participantsNCT07022002
What this trial is testing

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Who this might be right for
Locally Advanced, Recurrent or Metastatic Malignancies
Shenyang Sunshine Pharmaceutical Co., LTD. 340
Early research (Phase 1)Active Not RecruitingNCT05311397
What this trial is testing

A166 in Patients With Advanced Solid Malignant Tumors

Who this might be right for
Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 120
Testing effectiveness (Phase 2)Ended earlyNCT01569412
What this trial is testing

Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors

Who this might be right for
Her2/Neu Positive Advanced Solid Tumors
Krankenhaus Nordwest 14
Testing effectiveness (Phase 2)Looking for participantsNCT07512583
What this trial is testing

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 178
Testing effectiveness (Phase 2)Study completedNCT00900627
What this trial is testing

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Cancer
AstraZeneca 330
Early research (Phase 1)UnknownNCT06154343
What this trial is testing

GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd. 150
Early research (Phase 1)Study completedNCT04162327
What this trial is testing

A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor

Who this might be right for
Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd. 55
Early research (Phase 1)UnknownNCT05819684
What this trial is testing

SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumor
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 133
Early research (Phase 1)Ended earlyNCT05511844
What this trial is testing

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene Amplification+1 more
Orum Therapeutics USA, Inc. 25
Testing effectiveness (Phase 2)Looking for participantsNCT06015048
What this trial is testing

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Who this might be right for
HER2-expressing Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 364
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT07122063
What this trial is testing

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd. 266
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Early research (Phase 1)Active Not RecruitingNCT04294628
What this trial is testing

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI) 62
Testing effectiveness (Phase 2)Looking for participantsNCT06031584
What this trial is testing

BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Who this might be right for
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd. 42
Early research (Phase 1)Study completedNCT00207012
What this trial is testing

MAD Refractory: Solid Tumor QD w/o Break

Who this might be right for
HER2 or EGFR Expressing Advanced Solid Malignancies
Bristol-Myers Squibb 45
Early research (Phase 1)Study completedNCT04235101
What this trial is testing

Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

Who this might be right for
Solid Tumor
Byondis B.V. 32
Early research (Phase 1)Not Yet RecruitingNCT05320874
What this trial is testing

KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.

Who this might be right for
Advanced Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd. 232
Early research (Phase 1)Ended earlyNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 3
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Next Page